Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference121 articles.
1. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nature Rev. Cancer 1, 118–129 (2001).
2. Huston, J. S. & George, A. J. Engineered antibodies take center stage. Hum. Antibodies 10, 127–142 (2001).
3. Park, J. W. et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8, 1172–1181 (2002).Carefully controlled research study that describes the therapeutic effects in xenograft breast cancer models of anti-ERBB2-targeted immunoliposomes. This might be the first immunoliposome to enter clinical trials.
4. Drummond, D. C., Hong, K., Park, J. W., Benz, C. C. & Kirpotin, D. B. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam. Horm. 60, 285–332 (2000).
5. Senter, P. D. & Springer, C. J. Selective activation of anticancer produugs by monoclonal antibody–enzyme conjugates. Adv. Drug Deliv. Rev. 53, 247–264 (2001).
Cited by
1466 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献